Tenax Therapeutics, Inc.TENXNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P33
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -8.78% |
| Q3 2025 | 14.23% |
| Q2 2025 | 0.28% |
| Q1 2025 | 109.36% |
| Q4 2024 | 79.26% |
| Q3 2024 | 12.11% |
| Q2 2024 | 9.00% |
| Q1 2024 | -24.68% |
| Q4 2023 | 55.67% |
| Q3 2023 | 1.28% |
| Q2 2023 | -18.49% |
| Q1 2023 | -10.29% |
| Q4 2022 | 3.09% |
| Q3 2022 | 2.98% |
| Q2 2022 | -13.20% |
| Q1 2022 | 40.55% |
| Q4 2021 | -58.48% |
| Q3 2021 | 107.66% |
| Q2 2021 | -7.44% |
| Q1 2021 | -29.29% |
| Q4 2020 | 65.62% |
| Q3 2020 | 34.92% |
| Q2 2020 | -34.30% |
| Q1 2020 | -4.91% |
| Q4 2019 | 3.56% |
| Q3 2019 | 14.78% |
| Q2 2019 | -0.73% |
| Q1 2019 | -31.46% |
| Q4 2018 | 44.36% |
| Q3 2018 | -24.47% |
| Q2 2018 | 35.49% |
| Q1 2018 | -16.29% |
| Q4 2017 | 31.68% |
| Q3 2017 | -41.03% |
| Q2 2017 | 23.76% |
| Q1 2017 | -26.85% |
| Q4 2016 | 56.31% |
| Q3 2016 | 2.12% |
| Q2 2016 | -29.63% |
| Q1 2016 | 88.69% |